← All trials
NCT00004179
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 1999
- Primary completion
- Apr 1, 2004
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 475
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- British Columbia Cancer AgencyStudy chair
- Australasian Leukaemia and Lymphoma GroupCollaborator
- Nordic Lymphoma GroupCollaborator
- National Cancer Institute (NCI)Collaborator
- University of AmsterdamStudy chair
- Karolinska InstituteStudy chair
- Canadian Cancer Trials GroupCollaborator
- University of CambridgeStudy chair
- Peter MacCallum Cancer CentreStudy chair
- HOVON - Dutch Haemato-Oncology AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.